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Resveratrol Treatment after 
Status Epilepticus Restrains 
Neurodegeneration and Abnormal 
Neurogenesis with Suppression of 
Oxidative Stress and Inflammation
Vikas Mishra1,2,3, Bing Shuai1,2,3, Maheedhar Kodali1,2,3, Geetha A. Shetty1,2,3, 
Bharathi Hattiangady1,2,3, Xiaolan Rao1,2,3 & Ashok K. Shetty1,2,3
Antiepileptic drug therapy, though beneficial for restraining seizures, cannot thwart status 
epilepticus (SE) induced neurodegeneration or down-stream detrimental changes. We investigated 
the efficacy of resveratrol (RESV) for preventing SE-induced neurodegeneration, abnormal 
neurogenesis, oxidative stress and inflammation in the hippocampus. We induced SE in young rats 
and treated with either vehicle or RESV, commencing an hour after SE induction and continuing 
every hour for three-hours on SE day and twice daily thereafter for 3 days. Seizures were terminated 
in both groups two-hours after SE with a diazepam injection. In contrast to the vehicle-treated 
group, the hippocampus of animals receiving RESV during and after SE presented no loss of 
glutamatergic neurons in hippocampal cell layers, diminished loss of inhibitory interneurons 
expressing parvalbumin, somatostatin and neuropeptide Y in the dentate gyrus, reduced aberrant 
neurogenesis with preservation of reelin + interneurons, lowered concentration of oxidative stress 
byproduct malondialdehyde and pro-inflammatory cytokine tumor necrosis factor-alpha, normalized 
expression of oxidative stress responsive genes and diminished numbers of activated microglia. Thus, 
4 days of RESV treatment after SE is efficacious for thwarting glutamatergic neuron degeneration, 
alleviating interneuron loss and abnormal neurogenesis, and suppressing oxidative stress and 
inflammation. These results have implications for restraining SE-induced chronic temporal lobe 
epilepsy.
Multiple conditions including head trauma, stroke and Alzheimer’s disease can trigger status epilepticus 
(SE). Hippocampus is highly susceptible to SE where a cascade of morphological and functional changes 
collectively referred to as epileptogenesis occur over weeks and months after SE and cause temporal 
lobe epilepsy (TLE), typified by spontaneous recurrent seizures (SRS), and cognitive and mood dysfunc-
tion associated with declined neurogenesis1–6. In the realm of SRS occurring in the chronic phase after 
SE, early changes such as loss of subclasses of gamma-amino butyric acid (GABA)-ergic interneurons3, 
increased oxidative stress, inflammation characterized by reactive astrocytes and activated microglia7,8 
and abnormal neurogenesis exemplified by anomalous migration of newly born neurons into the dentate 
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hilus and the molecular layer have received great interest9–11. On the other hand, memory and mood 
impairments in the chronic phase after SE have been attributed to declined neurogenesis and loss of 
glutamatergic neurons in the hippocampus2,12–14. Antiepileptic drug (AED) therapy can stop SE in most 
instances but cannot adequately suppress SE-induced early detrimental changes described above5,15–17. 
Because these changes contribute to epileptogenesis, AED therapy has mostly failed to prevent the evo-
lution of SE into chronic TLE. Hence, an ideal neuroprotective strategy for SE should be capable of 
restraining glutamatergic and GABA-ergic neuron loss, oxidative stress, inflammation and aberrant 
neurogenesis. In this context, compounds and drugs having neuroprotective and/or antiepileptogenic 
properties are ideal for preventing SE-induced chronic hippocampal dysfunction typified by SRS, and 
cognitive and mood impairments.
Resveratrol (RESV), a polyphenol found abundantly in the skin of red grapes, appears to meet the 
above criteria as it can mediate a wide range of biological activities with no side effects18–21. The proper-
ties of RESV particularly relevant for neuroprotection and anti-epileptogenesis after SE include its ability 
for crossing the blood-brain barrier after systemic administration22, and diminishing oxidative stress23, 
apoptotic and necrotic cell death24 and neuroinflammation20,25,26. Studies in neurological disease models 
have also suggested that RESV is a potent neuroprotective compound27–30. Moreover, RESV adminis-
tration prior to SE induction or after focal injury can restrain neuron loss and oxidative stress22,26,31–33. 
However, the efficacy of RESV administration commencing after the onset of full-blown SE is unknown. 
Therefore, using a well-established kainate model of SE, we examined the effects of RESV treatment 
commencing an hour after SE for easing glutamatergic and GABA-ergic neuron loss, oxidative stress, 
inflammation and abnormal neurogenesis in the hippocampus, using immunohistochemical, biochemi-
cal and molecular biological methods and stereological cell counts.
Results
The time-line of experiments, and the vehicle (VEH), RESV and diazepam treatment regimen employed 
after SE onset, are illustrated in Fig. 1. Status epilepticus was induced in young adult rats through graded 
intraperitoneal injections of kainic acid (KA), as detailed in our previous studies12,34–36. Additional details 
on procedures and animal numbers utilized for various analyses are available in “Methods” section. From 
here onwards, animals receiving VEH during and after SE, and animals receiving RESV during and after 
SE, will be referred to as “SE-VEH animals” and “SE-RESV animals” respectively.
RESV treatment after the induction of SE did not affect behavioral seizures. The behavioral 
activity of animals that received graded intraperitoneal KA injections was carefully observed. In the first 
hour after SE onset, rats assigned to VEH and RESV groups displayed comparable episodes of stages IV 
and V seizures, typified by bilateral forelimb clonus or bilateral forelimb clonus with rearing and falling 
(SE-VEH animals, Mean ± SEM: 5.9 ± 1.4; SE-RESV animals, 6.4 ± 1.2, p > 0.05, n = 8–9). Treatment 
with VEH or RESV did not affect seizures in the second hour after SE, as animals in both groups 
exhibited similar numbers of stages IV–V seizures following the treatment (SE-VEH animals, 2.2 ± 0.9; 
Figure 1. A schematic showing the experimental design and the time-line of vehicle (VEH) or 
resveratrol (RESV) treatment. Status epilepticus (SE) was first induced in Fischer 344 rats through graded 
intraperitoneal injections of Kainic acid (KA). Animals received hourly injections of VEH or RESV for three 
hours on the day of SE (Day 1), which commenced an hour after the onset of SE. In the following 3 days 
(days 2–4), animals received twice daily (morning and evening) injections of VEH or RESV. The behavioral 
seizures in both VEH and RESV treated groups were terminated 2 hours after the induction of SE through 
an intraperitoneal injection of diazepam (5 mg/Kg). Subgroups of animals were euthanized 1 and 4 days 
after SE along with age-matched naïve control animals and tissues harvested for biochemical and molecular 
biological studies. Additional subgroups of animals were euthanized 4 days after SE via intracardiac 
perfusions for various immunohistochemical studies. M, morning; E, evening.
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SE-RESV animals, 2.5 ± 0.8, p > 0.05, n = 8–9). Thus, RESV treatment did not seem to affect the ongoing 
seizures in the second hour after SE onset. Furthermore, a subcutaneous injection of diazepam given 
two hours after SE onset terminated stages III-V behavioral seizures within 10–15 minutes of injection 
in both VEH and RESV treated groups.
RESV administration protected hippocampal glutamatergic neurons from SE-induced death. 
Immunostaining of brain sections through the hippocampus for NeuN visualized neurons in differ-
ent cell layers of the hippocampus (Fig.  2). The overall density of neurons in the DH, GCL, and CA1 
and CA3 cell layers of the hippocampus appeared clearly reduced in SE-VEH animals in comparison 
to age-matched naive control rats (Fig.  2(A1–B4)). In contrast, SE-RESV animals appeared to have 
similar density of neurons as naive control rats and greater density of neurons than SE-VEH animals 
(Fig. 2(C1–C4)). Stereological quantification of NeuN + neurons in different cell layers of the hippocam-
pus confirmed considerable loss of neurons in SE-VEH animals and no significant loss of neurons in 
rats receiving RESV (Fig. 2(D–G)). The overall loss in SE-VEH animals was 21% in the GCL (p < 0.01), 
41% in the DH (p > 0.05), 53% in the CA1 cell layer (p < 0.01), and 38% in the CA3 cell layer (p < 0.01). 
In contrast, SE-RESV animals displayed similar numbers of neurons as naive control rats in the GCL, 
DH, CA1 and CA3 pyramidal cell layers (p > 0.05, Fig. 2(D–G)). This quantification also revealed that 
SE-RESV animals displayed greater numbers of surviving neurons in GCL, DH, CA1 and CA3 cell layers 
than SE-VEH animals (p < 0.05-0.001, Fig. 2(D–G)). Thus, RESV treatment notably protected glutama-
tergic neurons in hippocampal cell layers from undergoing SE-induced death.
RESV treatment diminished SE-induced loss of subclasses of GABA-ergic interneurons 
expressing PV, SS and NPY. We examined the efficacy of RESV treatment to protect different sub-
classes of hippocampal GABA-ergic interneurons in the dentate gyrus (DG) against SE-induced loss. 
In comparison to naive control animals, SE-VEH animals displayed an apparently reduced density 
of interneurons expressing the calcium binding protein PV (Fig.  3(A1–C2)), and neuropeptides SST 
(Fig. 3(E1–G2)) and NPY (Fig. 4(A1–C2)) in the DG. Stereological quantification confirmed considerable 
loss of these interneurons. The reductions were 39% for PV + interneurons (p < 0.0001, Fig. 3(D)), 46% 
for SST + interneurons (p < 0.001, Fig. 3(H)), and 56% for NPY + interneurons (p < 0.0001, Fig. 4(D)). 
In contrast, SE-RESV animals showed reduced loss of interneurons in the DG (Fig. 3(D,H) and 4[D]). 
In comparison to naive control animals, the reductions were 18% for PV + interneurons (p < 0.05), 30% 
for SST + interneurons (p < 0.01) and 40% for NPY + interneurons (p < 0.0001). Additional analyses 
revealed that, in comparison to SE-VEH animals, the DG of SE-RESV animals contained greater num-
bers of interneurons expressing PV (34% more, p < 0.01), SST (30% more, p > 0.05), and NPY (37% 
more, p < 0.05, Figs  3(D,H)  and  4(D)). Thus, RESV administration during and after SE considerably 
restrained the loss of various subclasses of GABA-ergic interneurons in the DG of the hippocampus.
RESV administration during and after SE restrained abnormal hippocampal neurogenesis 
with preservation of interneurons expressing reelin. Newly born DCX + neurons incorpo-
rate solely into the SGZ-GCL in the DG of naive control animals (Fig.  5(A1,A2)). Hence, newly born 
DCX + neurons were either absent or rarely seen in the DH of these animals. In contrast, in SE-VEH 
animals, considerable numbers of newly born DCX + neurons migrated abnormally into the DH 
(Fig. 5(B1,B2, I)), which is a consistent effect of SE found in virtually all animal models of SE examined 
so far1,2,9,37. However, animals receiving RESV treatment after SE displayed considerably reduced num-
bers of newly born DCX + neurons in the DH (Fig.  5(C1,C2,  I), 59% reduction, p < 0.05), suggesting 
that RESV administration during and after SE onset can restrain the abnormal migration of newly born 
neurons. Examination of the extent of normal neurogenesis in the SGZ-GCL region did not show any 
apparent differences between SE-VEH and SE-RESV animals however.
We also examined and quantified the occurrence of basal dendrites projecting into the dentate hilus 
from DCX + newly born neurons that incorporated into the SGZ and GCL area with one or more major 
dendrites projecting into the dentate molecular layer (i.e. from relatively mature DCX + newly born 
neurons, Fig.  5(D,E)). SE-RESV animals displayed reduced percentages of DCX + neurons with basal 
dendrites than SE-VEH animals (Fig.  5(J), 46% reduction, p < 0.01). Thus, in comparison to SE-VEH 
animals, SE-RESV animals exhibited considerably reduced abnormal neurogenesis. Because reelin is 
involved in the appropriate migration of DCX + newly born neurons into the SGZ-GCL area and reelin 
is derived from subclasses of interneurons, we evaluated the number of interneurons expressing reelin in 
DH (Fig. 5(F1–H2)). In comparison to naive control animals, SE-VEH animals showed greatly reduced 
numbers of interneurons expressing reelin in the DH (52% reduction, p < 0.01, Fig. 5(K)). However, the 
loss of reelin + interneurons in the DH was not significant in SE-RESV animals (p > 0.05, Fig.  5(K)). 
Thus, RESV administration during and after SE restrained the extent of abnormal hippocampal neuro-
genesis through considerable protection of reelin + neurons in the DH.
RESV treatment eased SE-induced oxidative stress. Both MDA (a byproduct of lipid perox-
idation and an important biomarker of membrane damage) and 4-HNE (α , β -unsaturated hydroxy-
alkenal produced by lipid peroxidation in cells) levels were increased at 1-day after SE in VEH-treated 
rats, implying significantly enhanced oxidative stress after SE in the hippocampus (Fig.  6(A1,A2)). In 
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comparison to naive control animals, the increases were 253% for MDA (p < 0.05) and 31% for 4-HNE 
(p < 0.05). Interestingly, RESV treatment did not significantly alter MDA and 4-HNE levels at 1-day after 
SE, as SE-RESV animals displayed 208% greater MDA and 25% greater 4-HNE levels than naive control 
Figure 2. Resveratrol (RESV) treatment after status epilepticus (SE) greatly restrained 
neurodegeneration in the dentate hilus (DH), the granule cell layer (GCL) and the hippocampal 
CA1 and CA3 pyramidal cell layers. A1, B1 and C1 show neuron-specific nuclear antigen (NeuN) 
immunostaining of the hippocampus in a naïve control rat (A1) and rats that received vehicle (VEH; B1) 
or RESV (C1) after SE. Figures A2-A4, B2-B4 and C2-C4 illustrate enlarged view of the dentate gyrus 
(A2,B2C2), CA1 subfield (A3,B3,C3) and CA3 subfield (A4,B4,C4) from A1, B1 and C1. Scale bar, A1, B1 
and C1, 500 μ m; A2-A4, B2-B4 and C2-C4, 200 μ m. Bar charts compare numbers of NeuN + neurons in 
different cells layers of the hippocampus between naïve control rats and rats that received VEH or RESV 
after SE. Note that, in comparison to naïve control rats, rats receiving VEH after SE display clearly reduced 
numbers of neurons in the DH (D), the granule cell layer (GCL; E) and the CA1 and CA3 pyramidal cell 
layers (F,G). Contrastingly, in rats receiving RESV during and after SE, numbers of neurons in these cell 
layers remain comparable to those in naïve control rats (D–G). *p < 0.05; **p < 0.01; ***p < 0.001; NS, not 
significant.
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animals (p < 0.05-0.01, Fig.  6(A1,A2)). However, major difference in MDA concentration emerged 
between SE-VEH and SE-RESV groups at 4 days after SE. While SE-VEH animals exhibited 83% greater 
MDA levels than naive control rats (p < 0.01), SE-RESV animals displayed levels of MDA that are highly 
comparable to naive control animals (p > 0.05, Fig.  6(A3)). Consequently, SE-VEH animals had 120% 
greater MDA concentration than SE-RESV animals at 4-days after SE (p < 0.01, Fig. 6(A3)). Thus, 4-days 
of RESV treatment eliminated SE-induced increased oxidative stress in the hippocampus.
RESV treatment normalized the expression of many oxidative stress response genes. Because 
MDA concentration was stabilized to baseline levels with 4 days of RESV treatment after SE, we examined 
Figure 3. Resveratrol (RESV) treatment after status epilepticus (SE) lowered the loss of interneurons 
expressing parvalbumin (PV) and somatostatin (SST) in the dentate gyrus (DG). Figures A1, B1 and 
C1 show the distribution of PV + interneurons in the DG from a naïve control rat (A1) and rats that 
received vehicle (VEH; B1) or RESV (C1) after SE. Figures A2, B2 and C2 are magnified views of regions 
from A1, B1 and C1. Figures E1, F1 and G1 show the distribution of SST + interneurons in the DG from 
a naïve control rat (E1) and rats that received VEH (F1) or RESV (C1) after SE. Figures E2, F2 and G2 
are magnified views of regions from E1, F1 and G1. DH, Dentate hilus; GCL, granule cell layer. Scale bar: 
A1, B1, C1, E1, F1 and G1, 200 μ m; A2, B2, C2, E2, F2 and G2, 100 μ m. Bar charts compare numbers of 
interneurons positive for PV (D) and SST (H) in the DG between naïve control rats and rats that received 
VEH or RESV after SE. Note that, in comparison to naïve control rats, rats receiving VEH after SE display 
considerable reductions in numbers of PV + and SST + interneurons. In contrast, rats receiving RESV 
during and after SE display moderate loss of PV + and SST + interneuron numbers and hence exhibit greater 
numbers surviving PV + and SST + interneurons than rats receiving VEH after SE. *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001.
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whether this regulation is also evident through the expression pattern of genes that respond to oxidative 
stress. Among 84 genes examined through qRT-PCR array, a fraction of genes showed significant dif-
ferences in their expression between naive control, SE-VEH and SE-RESV animals (p < 0.05, one-way 
ANOVA, Fig.  6(B1–B11)): (1) CCL5—a gene encoding T-cell specific RANTES protein (C-C Motif 
chemokine 5) having a role in recruiting leukocytes into inflammatory sites (Fig. 6(B2)). (2) GPX7 and 
GPX1—genes encoding glutathione peroxidases 1 and 7, which are enzymes that couple the oxidation 
of reduced glutathione to the detoxification of peroxides (Fig. 6(B3,B8)). (3) PRDX4 and PRDX2—genes 
encoding peroxiredoxins 4 and 2, which are antioxidant enzymes involved in reducing hydrogen per-
oxide and alkyl hydroperoxides to water and alcohol with the use of reducing equivalents derived from 
thiol-containing donor molecules (Fig.  6(B4,B9)). (4) TXN1—a gene encoding thioredoxin 1, which 
participates in various redox reactions through the reversible oxidation of its active center dithiol to a 
disulfide and catalyzes dithiol-disulfide exchange reactions (Fig. 6(B5)). In addition, it plays a role in the 
reversible S-nitrosylation of cysteine residues in target proteins, and thereby takes part in the response 
to intracellular nitric oxide. (5) PARK7—a gene encoding Parkinson protein 7, which functions as a 
redox-sensitive chaperone (a sensor for oxidative stress) and protects neurons against oxidative stress and 
cell death (Fig. 6(B6)). (6) VIMP—a gene encoding VCP interacting membrane protein involved in the 
degradation process of misfolded endoplasmic reticulum luminal proteins (Fig. 6(B7)). (7) SOD1—a gene 
encoding the most abundant cytosolic superoxide dysmutase 1, which binds to molecules of copper (Cu) 
and zinc (Zn) to break down toxic, charged oxygen molecules called superoxide radicals (Fig. 6(B10)). (8) 
GCLC—a gene encoding glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), which is the 
first rate-limiting enzyme of glutathione synthesis. Of the above genes, the expression of CCL5, GPX7, 
PRDX4 and GPX1 was significantly upregulated in SE-VEH animals (p < 0.05 in comparison naive 
Figure 4. Resveratrol (RESV) treatment after status epilepticus (SE) moderated the loss of interneurons 
expressing neuropeptide Y (NPY) in the dentate gyrus (DG). Figures A1, B1 and C1 show the distribution 
of NPY + interneurons in the DG from a naïve control rat (A1) and rats that received vehicle (VEH; 
B1) or RESV (C1) after SE. Figures A2, B2 and C2 are magnified views of regions from A1, B1 and C1. 
DH, Dentate hilus; GCL, granule cell layer. Scale bar: (A1,B1,C1) 200 μ m; (A2,B2,C2) 100 μ m. Bar chart 
compares the numbers of interneurons positive for NPY in the DG between naïve control rats and rats 
that received VEH or RESV after SE. Note that, in comparison to naïve control rats, rats receiving VEH 
after SE display a major reduction in numbers of NPY + interneurons. In contrast, rats receiving RESV 
during and after SE display reduced loss of NPY + interneurons and hence show greater numbers surviving 
NPY + interneurons than rats receiving VEH after SE. DH, Dentate hilus; GCL, granule cell layer. *p < 0.05; 
****p < 0.0001.
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control rats) but normalized to control levels in SE-RESV animals (p > 0.05) (Fig.  6(B2–B4,B8)). On 
the other hand, the expression of genes TXN1, PARK7 and VIMP was modestly upregulated in SE-VEH 
animals (p > 0.05) but RESV treatment for 4 days significantly reduced their expression (p < 0.05 in 
Figure 5. Resveratrol (RESV) treatment after status epilepticus (SE) curbed abnormal hippocampal 
neurogenesis with preservation of interneurons expressing reelin. Figures A1, B1 and C1 show the 
distribution of doublecortin (DCX) positive newly born neurons in the dentate gyrus (DG) subgranular 
zone (SGZ), granule cell layer (GCL) and hilus (DH) from a naïve control rat (A1) and rats that received 
vehicle (VEH; B1) or RESV (C1) after SE. A2, B2 and C2 are magnified views of regions from A1, B1 
and C1 showing the morphology of DCX + neurons. Note that, DCX + neurons are restricted to the SGZ-
GCL with dendrites projecting into the molecular layer in the DG of naive control rat (A1, A2) whereas, 
in the DG of rat receiving VEH after SE, DCX + neurons have moved mostly into the DH (B1, B2), 
implying abnormal migration. In contrast, in the DG of rat receiving RESV during and after SE, majority of 
DCX + neurons remained in the SGZ-GCL, depicting minimal abnormal migration. Figures D and E show 
DCX + newly born granule cells exhibiting basal dendrites projecting into the DH in rats that received VEH 
(D) or RESV (E) after SE. Figures F1, G1 and H1 show the distribution of reelin + interneurons in the DH 
from a naïve control rat (F1) and rats that received VEH (G1) or RESV (H1) after SE. F2, G2 and H2 are 
magnified views of regions from F1, G1 and H1. Scale bar: A, B1, C1, F1, G1 and H1, 200 μ m; A2, B2, C2, 
F2, G2 and H2, 100 μ m; D and E, 50 μ m. Bar charts in I and J compare the numbers of DCX + neurons 
in the DH (I) and percentages of DCX + neurons in the GCL exhibiting basal dendrites (J). Rats receiving 
RESV during and after SE display reduced numbers of DCX + neurons into the DH and reduced percentages 
of DCX + neurons exhibiting basal dendrites. Bar chart in K compares the numbers of reelin + interneurons 
between groups. Rats receiving VEH after SE show considerable loss of reelin + interneurons in comparison 
to the other two groups, whereas rats receiving RESV during and after SE demonstrate no loss of 
reelin + interneurons. *p < 0.05; **p < 0.01; NS, not significant.
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Figure 6. Resveratrol (RESV) treatment for 4 days normalized status epilepticus (SE) induced 
increased oxidative stress in the hippocampus. Bar charts in A1, A2 and A3 compare concentrations 
of malondialdehyde (MDA; A1,A3) and 4-hydroxynoneal (4-HNE; A2) between different groups. When 
measured a day after SE, rats receiving vehicle (VEH) or RESV showed increased concentration of MDA 
(A1) and 4-HNE (A2) in comparison to naive control rats. However, when measured 4 days after SE, 
MDA concentration was normalized to control levels in rats receiving RESV but remained upregulated in 
rats receiving VEH after SE (A3), implying the beneficial effects of RESV treatment for 4 days after SE. 
Figure B1 illustrates the expression (heat map) of select oxidative stress responsive and antioxidant genes 
measured through quantitative real time PCR array in the hippocampus. Note that, in comparison to their 
expression in naive control rats, many genes show a trend towards increased expression in rats receiving 
VEH after SE but normalized expression in rats receiving RESV during and after SE (B1), suggesting 
extinction of increased oxidative stress with RESV treatment. Bar charts in B2-B11 compare the expression 
of specific genes between the three groups. Note that, RESV treatment after SE normalized the expression 
of genes CCL5, GPX7, PRDX4, TXN1, PARK7, VIMP and GPX1 to control levels (B2–B8) and lowered 
the expression of genes PRDX2, SOD1 and GCLC to below control levels (B9–B11), implying considerable 
moderation of oxidative stress in the hippocampus by RESV treatment.
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comparison to SE-VEH animals and p > 0.05 in comparison to naive controls, Fig. 6(B5,B6)). The expres-
sion of genes PRDX2, SOD1 and GCLC in SE-VEH animals remained similar to naive control rats but 
RESV treatment significantly reduced their expression (p < 0.05, in comparison to both SE-VEH animals 
and naive control rats, Fig. 6(B9–B11)).
Furthermore, though not significant statistically, several other genes responsive to oxidative stress 
displayed a trend towards reduced expression in SE-RESV animals in comparison to SE-VEH ani-
mals (Fig.  6(B1)). These include: (1) CAT—a gene encoding catalase, which breaks down hydrogen 
peroxide (H2O2) molecules into oxygen (O2) and water (H2O). (2) NUDT1—a gene encoding Nudix 
(Nucleoside Diphosphate Linked Moiety X) -Type Motif 1, which acts as a sanitizing enzyme for oxidized 
nucleotide pools to prevent cell dysfunction and death induced by oxidative stress. (3) IDH1—a gene 
encoding the production of isocitrate dehydrogenase 1, which converts isocitrate to 2-ketoglutarate to 
produce NADPH necessary for many cellular processes and protection against ROS. (4) PRDX1—a gene 
encoding peroxiredoxin 1 involved in reducing hydrogen peroxide. (5) SERPINB 1B—a gene encod-
ing Ovalbumin (Serpin Peptidase Inhibitor Clade B), which inhibits the neutrophil-derived proteinases 
neutrophil elastase, cathepsin G, and proteinase-3 to protect tissues from damage at inflammatory sites. 
(6) SEPP1—a gene encoding Selenoprotein P, Plasma 1, which is believed to be responsible for some of 
the extracellular antioxidant defense properties of selenium. (7) FTH1—a gene encoding heavy subunit 
of ferritin, which stores iron in a soluble and nontoxic state. (8) APC—a gene encoding tumor suppressor 
Figure 7. Resveratrol (RESV) treatment for 4 days normalized status epilepticus (SE) induced increased 
concentration of tumor necrosis factor-alpha (TNF-α) in the hippocampus. Bar charts in A1-A4 
compare concentrations of pro-inflammatory cytokines TNF-α (A1,A3) and interleukin-6 (IL-6; A2,A4) 
between different groups. When measured a day after SE, rats receiving vehicle (VEH) or RESV showed no 
increase in concentrations of TNF-α (A1) or IL-6 (A2) in comparison to naive control rats. However, when 
measured 4 days after SE, TNF-α concentration was normalized to control levels in rats receiving RESV but 
was upregulated in rats receiving VEH after SE (A3). On the other hand, IL-6 concentration did not vary 
between groups even at 4 days post-SE.
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adenomatous polyposis coli (APC) protein having a role in several cellular processes. (9) APOE—a gene 
encoding apolipoprotein E, which is a very low-density lipoprotein involved in removing cholesterol. 
Thus, in comparison to SE-VEH animals, SE-RESV animals displayed diminished expression of multiple 
genes related to oxidative stress. Because these genes typically exhibit increased expression in response 
to oxidative stress, the results imply normalization of oxidative stress with RESV treatment, consistent 
with MDA results described above.
Additionally, five genes relevant to oxidative stress showed reduced expression in SE-RESV animals 
in comparison to control animals (p < 0.05, data not illustrated). These include: GSTP1, which encodes 
glutathione s-transferase Pi 1 involved in detoxification by catalyzing the conjugation of many hydro-
phobic and electrophilic compounds with reduced glutathione; SOD2, which encodes mitochondrial 
protein superoxide dysmutase 2 that binds to the superoxide byproducts of oxidative phosphorylation 
and converts them to hydrogen peroxide and diatomic oxygen; GSR, which encodes glutathione reduc-
tase, a central enzyme of cellular antioxidant defense that reduces oxidized glutathione disulfide (GSSG) 
to the sulfhydryl form of GSH, which is an important cellular antioxidant; IFT172, which encodes an 
oxygen transporter, intraflagellar transport 172 Homolog; and FANCC, which encodes Fanconi anemia, 
complementation group C involved in DNA repair. However, the expression of these genes did not dif-
fer between SE-RESV and SE-VEH animals as well as between naive and SE-VEH animals. Thus, the 
expression of multiple genes that typically display upregulated expression to increased oxidative stress 
was either normalized to control levels or pushed to levels lower than that of controls by RESV treat-
ment, which is suggestive of greatly diminished oxidative stress in the hippocampus of rats that received 
RESV after SE.
RESV treatment after SE decreased TNF-α concentration and the numbers of activated micro-
glia. Analyses using ELISA showed no changes in the concentration of pro-inflammatory cytokines 
TNF-α and IL-6 at 1-day after SE in SE-VEH and SE-RESV animals, in comparison to naive control 
animals (Fig.  7(A1,A2)). At 4-days post-SE, TNF-α protein concentration was increased in SE-VEH 
animals (p <  0.05, Fig.  7(A3)) but SE-RESV animals displayed concentrations comparable to those in 
naive control rats (p > 0.05, Fig. 7(A3)). However, IL-6 concentrations remained similar between groups 
at 4-days post-SE (Fig. 7(A4)). Analyses using ED-1 immunohistochemistry at 4-days post-SE revealed 
the presence of abundant activated microglia in the hippocampus of SE-VEH animals (Fig. 8(A1–A4)). 
However, SE-RESV animals demonstrated clearly reduced density of ED-1+ activated microglia in the 
hippocampus (Fig.  8(B1–B4)). Stereological quantification of ED-1+ cells confirmed a clear reduction 
in the number of ED-1+ activated microglia in SE-RESV animals (Fig. 8(C1–C4)). Although the reduc-
tions were modest in the DG (13% reduction, p > 0.05, Fig. 8(C1)) and the CA3 subfield (20% reduction, 
p > 0.05, Fig.  8(C3)), it was considerable for the CA1 subfield (46% reduction, p < 0.01, Fig.  8(C2)). 
When the hippocampus was taken in its entirety, SE-RESV animals displayed significantly reduced num-
bers of activated microglia (30% reduction, p < 0.05, Fig. 8(C4)). Thus, 4 days of RESV treatment pre-
vented increases in TNF-α protein concentration as well as reduced the numbers of activated microglia.
SE or RESV treatment after SE did not alter the expression of select genes related to inflam-
mation, longevity and cognition. Measurement of genes related to inflammation in the hippocam-
pus at 1-day after SE revealed no differences in the expression of IL-1β , NF-kB, IFN-γ, IL-4, IL-10 and 
MPO between SE-VEH, SE-RESV and naive control rats (p > 0.05, Table 1). The expression of TNF-α 
gene was enhanced in both SE-VEH and SE-RESV animals in comparison to naive control animals at 
this time point (p < 0.001, Table 1). No changes were however observed in the expression of any of the 
above 7 genes when examined at 4-days post-SE (Table 2). Animals receiving RESV during and after SE 
also did not display any increase in the expression of the longevity gene SIRT1 or FOXO3, a gene whose 
expression is dependent on SIRT1 activity and is important for cognitive function and synaptic plasticity. 
This was evidenced through similar expression of SIRT1 and FOXO3 between naive control animals and 
animals receiving VEH or RESV after SE when quantified at 1- and 4-days post-SE (p > 0.05, Tables 1 
and 2). Thus, RESV mediated neuroprotection against SE did not seem to involve major modulation of 
the expression of genes related to inflammation, longevity or cognition.
Discussion
This study provides the first evidence that RESV treatment commencing an hour after SE onset is effi-
cient for protecting glutamatergic neurons in different hippocampal subfields, reducing the loss of several 
subclasses of GABA-ergic interneurons in the DG, and stemming anomalous hippocampal neurogenesis. 
Furthermore, RESV treatment mediated restrained neurodegeneration was allied with normalization of 
seizure-induced increased oxidative stress and modulation of inflammation, and diminished abnormal 
neurogenesis was accompanied with the preservation of reelin + interneurons in the DH. Because sub-
stantial interneuron loss, incessant oxidative stress and inflammatory activity, and aberrant neurogenesis 
are believed to be key contributors to epileptogenic processes that ensue after SE, these outcomes have 
great value towards developing a therapeutic regimen that curbs the progression of initial hippocampal 
injury into chronic TLE.
Status epilepticus emerges when sustained activation of glutamate receptors occurs in hippocampal 
principal neurons. Such stimulation primarily triggers prolonged hyperactivity of these neurons and 
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then encompasses additional neuronal populations38. Synchronized and protracted hyperactivity leads 
to seizures accompanied with increased oxidative stress within neurons39. This ultimately initiates exci-
totoxic neuronal death in hippocampal regions such as DH comprising mainly distinct subpopulations 
of GABA-ergic interneurons and CA1 and CA3 cell layers filled mostly with glutamatergic pyramidal 
neurons. While the foremost neuron loss may cease with SE extinction, changes such as oxidative stress 
linger for extended periods after SE40. Both neurodegeneration and oxidative stress cause considerable 
Figure 8. Resveratrol (RESV) treatment for 4 days reduced status epilepticus (SE) induced 
ED1 + activated microglia in the hippocampus. Figures A1 and B1 show the distribution of 
ED-1 + activated microglia in the hippocampus of rats receiving vehicle (VEH; A1) or RESV (B1) after 
SE. A2, A3 and A4 are magnified views of regions from A1 whereas B2, B3 and B4 are magnified views 
of regions from B1, showing the distribution of ED-1 + microglia in the dentate gyrus (DG; A2,B2), CA1 
subfield (A3,B3) and the CA3 subfield (A4,B4). DH, Dentate hilus; GCL, granule cell layer. Scale bar, A1 
and B1, 500 μ m; A2–A4 and B2-B4, 200 μ m. Bar charts in C1-C4 compare numbers of ED-1 + activated 
microglia between the two groups in the DG (C1), CA1 subfield (C2), CA3 subfield (C3) and the entire 
hippocampus (C4). Note that, RESV treatment significantly reduced numbers of ED-1 + activated microglia 
in the CA1 subfield (A3,B3,C2) and when the hippocampus was taken as a whole (A1,B1,C4). *p < 0.05; 
**p < 0.01.
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inflammation with elevated levels of pro-inflammatory cytokines and activation of microglia41. Because 
all of these changes can participate in the evolution of initial SE-induced injury into chronic TLE, an 
ideal therapeutic strategy for SE therefore should be capable of protecting both principal and GABA-ergic 
neurons through suppression of oxidative stress and inflammation. It has been apparent from multiple 
studies that AEDs cannot accomplish these beneficial effects in spite of their ability to stop SE in many 
conditions42. The results of this study however demonstrate that RESV administration after SE has con-
siderable promise for providing these beneficial effects.
The amount of neuroprotection seen with RESV administration was robust in this study. This was 
demonstrated by no significant neuron loss in the GCL, DH, and CA1 and CA3 pyramidal cell lay-
ers of SE-RESV animals, in contrast to neuron loss reaching 21-53% in these regions of SE-VEH ani-
mals. Moreover, SE-RESV animals displayed greater level of preservation of subclasses of GABA-ergic 
interneurons expressing PV, SST and NPY. This was evident from 30-37% greater numbers of these 
interneurons in the DG of SE-RESV animals at 4 days after SE, in comparison to the DG of SE-VEH 
animals. Although RESV treatment mediated interneuron protection is partial, this has considerable 
importance as studies have shown that severe loss of interneurons expressing calcium-binding proteins 
(e.g. PV + interneurons) and/or neuropeptides (e.g. SS + and NPY + interneurons) leads to chronic 
TLE exemplified by robust spontaneous recurrent seizures and cognitive and mood impairments12,43–46. 
The potential of RESV as a neuroprotective compound has been known from studies in several other 
neurological disease models. However, its ability for neuroprotection when applied after SE onset was 
Gene
Naïve Control SE-VEH SE-RESV ANOVA
Mean ± S.E.M Mean ± S.E.M Mean ± S.E.M p-value
IL1β 0.000220 ± 0.00002 0.000313 ± 0.000047 0.0002425 ± 0.000019 p > 0.05
TNF-α 0.000203 ± 0.00007 0.00070 ± 0.000038 0.00058 ± 0.000046 p < 0.0001
(Naive vs SE-VEH, p < 0.001; Naive vs SE-RESV, p < 0.001, SE-VEH vs SE-RESV, p > 0.05)
NF-kB 0.00476 ± 0.00098 0.009995 ± 0.0011 0.007802 ± 0.00162 p > 0.05
IFN-γ 0.00002 ± 0.000002 0.000014 ± 0.000002 0.0000115 ± 0.0000007 p > 0.05
IL4 0.000084 ± 0.000009 0.00017 ± 0.0000077 0.00018 ± 0.000034 p > 0.05
IL10 0.003974 ± 0.001234 0.00263 ± 0.000555 0.00360 ± 0.00048 p > 0.05
MPO 0.000035 ± 0.000009 0.000121 ± 0.000039 0.000085 ± 0.0000145 p > 0.05
SIRT1 0.00745 ± 0.0007 0.008357 ± 0.0007 0.008581 ± 0.00071 p > 0.05
FOXO3 0.01386 ± 0.0018 0.01015 ± 0.0008 0.01125 ± 0.00072 p > 0.05
Table 1.  Expression of Select Genes Related to Inflammation, Longevity and Cognition when examined 
a day after status epilepticus (SE). The numbers depict 2^delta Ct values. IL1β , interleukin 1-beta; TNF-α , 
tumor necrosis factor-alpha; NF-kB, nuclear factor of kappa light polypeptide gene enhancer in B-cells; IFN-γ, 
interferon-gamma; MPO, myeloperoxidase; IL4, interleukin 4; IL10, interleukin 10; SIRT1, sirtuin 1; FOXO3, 
forkhead box O3.
Gene
Naïve Control SE-VEH SE-RESV ANOVA
Mean ± S.E.M Mean ± S.E.M Mean ± S.E.M p-value
IL1β 0.000220 ± 0.00002 0.000155 ± 0.000032 0.0001954 ± 0.000056 p > 0.05
TNF-α 0.000203 ± 0.00007 0.000304 ± 0.000046 0.0002614 ± 0.000025 p > 0.05
NF-kB 0.00476 ± 0.00098 0.005360 ± 0.000206 0.005769 ± 0.000647 p > 0.05
IFN-γ 0.00002 ± 0.000002 0.005914 ± 0.003413 0.005713 ± 0.0035 p > 0.05
IL4 0.000084 ± 0.000009 0.000066 ± 0.000018 0.000052 ± 0.000005 p > 0.05
IL10 0.003974 ± 0.001234 0.000376 ± 0.000340 0.001913 ± 0.000865 p > 0.05
MPO 0.000035 ± 0.000009 0.000032 ± 0.000009 0.000022 ± 0.000004 p > 0.05
SIRT1 0.00745 ± 0.0007 0.005498 ± 0.000476 0.005553 ± 0.00049 p > 0.05
FOXO3 0.01386 ± 0.0018 0.00565 ± 0.003343 0.008032 ± 0.00358 p > 0.05
Table 2.  Expression of Select Genes Related to Inflammation, Longevity and Cognition when examined 
four days after status epilepticus (SE). The numbers depict 2^delta Ct values. IL1β , interleukin 1-beta; TNF-α , 
tumor necrosis factor-alpha; NF-kB, nuclear factor of kappa light polypeptide gene enhancer in B-cells; IFN-γ, 
interferon-gamma; MPO, myeloperoxidase; IL4, interleukin 4; IL10, interleukin 10; SIRT1, sirtuin 1; FOXO3, 
forkhead box O3.
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unknown as previous studies in animal models were focused on examining the neuroprotective proper-
ties of RESV when administered prior to SE induction or after focal hippocampal injury induced under 
anesthesia20,22,26,31,47. The present study, by directly addressing this issue, however provided compelling 
evidence that RESV is neuroprotective even when applied after the onset of full-blown SE. Furthermore, 
RESV treatment did not seem to have anti-seizure effects, as animals treated with VEH or RESV dis-
played similar numbers of stages IV-V behavioral seizures in the first hour after treatment (i.e. in the 
second hour after SE onset). However, this finding needs detailed evaluation in the future studies using 
continuous EEG recordings after VEH or RESV treatment as well as following SE termination with 
diazepam injection. Such EEG studies would also be useful to detect the potential interactions between 
diazepam and RESV on seizure termination because a previous study has reported that higher doses of 
RESV can inhibit CYP3A4, a metabolic enzyme capable of increasing the bioavailability of diazepam48.
Nonetheless, analyses of biochemical, molecular and cellular changes in the hippocampus suggest that 
containment of SE-induced upsurge in oxidative stress and modulation of inflammation underlie RESV 
mediated neuroprotection. This is evinced by the following observations. Concerning oxidative stress, 
SE-RESV animals displayed MDA and 4-HNE (markers of lipid peroxidation) in the hippocampus to 
levels seen in SE-VEH animals when examined a day after SE, suggesting that RESV treatment for a brief 
period is insufficient for normalizing oxidative stress. However, 4 days after SE, RESV treated rats main-
tained hippocampal MDA to levels found in naïve control animals whereas SE-VEH animals sustained 
increased levels of MDA. Furthermore, the expression of many genes that classically exhibit upregulated 
expression in response to mounted oxidative stress was stabilized to control levels with RESV treatment. 
These comprise genes encoding proteins that are important for: (i) recruiting leukocytes into inflamma-
tory sites (CCL5); (ii) detoxification of peroxides (GPX1, GPX7); (iii) reducing hydrogen peroxide, alkyl 
hydroperoxides (PRDX2, PRDX4) and intracellular nitric oxide (TXN1); (iv) promoting redox-sensitive 
chaperone activity (PARK7); (v) degradation of misfolded endoplasmic reticulum proteins (VIMP); (vi) 
reducing superoxide radicals (SOD1); and (vii) synthesizing glutathione (GCLC). The various other 
genes which respond to oxidative stress also showed a drift towards diminished expression in RESV 
treated rats, which include CAT, NUDT1, IDH1, PRDX1, SERPINB 1B, SEPP1, FTH1, APC and APOE. 
Intriguingly, RESV treatment after SE reduced the expression of some oxidative stress response genes 
(GSTP1, SOD2, GSR, IFT172, FANCC) to levels lesser than in naive control animals. Taken together, 
these observations underscore that 4 days of RESV treatment after SE is adequate for effecting oxidative 
stress to normal levels.
Restraining oxidative stress after SE has enormous value because increased oxidative stress has been 
shown to promote chronic neurodegeneration and dysfunction of surviving neurons in many neurolog-
ical diseases, and elevated concentration of MDA is indeed seen in epileptic patients40,49. Normalization 
of oxidative stress by RESV treatment detected here is consistent with findings in other disease models 
using RESV50,51. However, RESV treatment for SE is likely to be effective only when oxidative stress is 
one of the prominent initial outcomes of SE. This is evident from an acute seizure study using neonatal 
animals, where no benefit of RESV treatment was observed on SE-induced neurodegeneration because 
SE in neonatal animals is not associated with increased oxidative stress52. Thus, RESV treatment for SE 
may be more suitable for the adult and aged populations where oxidative stress is one of the major initial 
pathological alterations.
The modulation of inflammation by RESV treatment was mainly evident from regulation of TNF-α 
protein concentration to control levels and reduced numbers of activated microglia at 4 days after SE. 
However, examination of the expression of select genes encoding pro-inflammatory and antiinflamma-
tory cytokines and NF-κ B (a regulator of inflammation53,54) did not reveal significant alterations between 
groups except for TNF-α gene, which showed increased expression in both SE-VEH and SE-RESV ani-
mals a day after SE. Likewise, SE-RESV animals did not exhibit activation of the longevity gene SIRT1 
or its downstream target FOXO3 likely due to a shorter duration and lower dose of RESV treatment. 
Thus, RESV-mediated suppression of SE-induced inflammation did not involve modulation of NF-κ B 
or SIRT1 activity. Considering these, the likely mechanism by which RESV modulated inflammation is 
via repression of oxidative stress after SE, which greatly reduced neuronal loss and hence severe inflam-
mation did not ensue in SE-RESV animals. Regardless of the mode of action, reduced inflammation 
observed after SE with RESV intervention has implications because persistent inflammation is one of 
the key players in the evolution of neurodegenerative diseases including TLE55. For instance, increased 
levels of pro-inflammatory cytokines are consistently seen in the epileptic brain56. The sources of these 
pro-inflammatory cytokines in the brain are activated microglia and reactive astrocytes. Microglia cells 
are the resident macrophages in the brain, and in normal conditions, they are known to probe their envi-
ronment57. When they sense injury signals, they get activated and release pro-inflammatory cytokines56. 
Thus, normalization of TNF-α concentration and reduced numbers of ED-1+ activated microglia in 
SE-RESV animals imply that RESV administration is effective for restraining SE-induced inflammation.
Another exciting aspect of RESV treatment mediated benefits after SE was its ability to restrain abnor-
mal neurogenesis. Abnormal neurogenesis, typified by aberrant migration of newly born neurons into 
the DH and occurrences of basal dendrites from neurons that incorporate into the GCL, is a common 
phenomenon after SE58. Indeed, abnormal neurogenesis was apparent in SE-VEH animals but clearly 
reduced in SE-RESV animals. Suppression of SE-induced abnormal neurogenesis through RESV admin-
istration has significance because multiple studies have shown that aberrant neurogenesis promotes the 
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development of epileptogenic circuitry between granule cells displaced into the DH and CA3 pyramidal 
neurons, and between basal dendrites of granule cells projecting into the DH and granule cell axons. 
Although conclusive evidence showing that these abnormalities alone are sufficient to cause chronic TLE 
is lacking59, their contribution towards occurrences of spontaneous recurrent seizures in the chronic 
phase after SE has been well recognized37,60–65. To understand the mechanism underlying RESV-mediated 
suppression of abnormal neurogenesis, we quantified reelin + interneurons in the DH. This is because, 
a previous study has demonstrated that migration of DCX + newly born neurons from the SGZ to 
GCL is guided by reelin protein secreted by reelin + interneurons in the DH and substantial loss of 
reelin producing neurons can promote abnormal migration of newly born neurons into the DH66. Our 
analysis confirmed the occurrence of abnormal neurogenesis in association with substantial loss of ree-
lin + interneurons in SE-VEH animals and reduced extent of abnormal neurogenesis with preservation 
of reelin + interneurons in SE-RESV animals. Thus, RESV administration restrained abnormal neuro-
genesis through preservation of reelin + interneurons and this protection is likely a result of suppression 
of oxidative stress and inflammation mediated by RESV.
Examination of the extent of normal neurogenesis in the SGZ-GCL region did not show apparent 
differences between SE-VEH and SE-RESV animals. Our recent study using aged animals has however 
shown increased normal neurogenesis with four weeks of RESV treatment67. Lack of increase in normal 
neurogenesis with RESV treatment in the current study likely reflects a shorter duration of RESV admin-
istration (4 days) vis-à-vis 4 weeks of RESV treatment employed in our previous study67.
Conclusion and Future Studies
This study provides novel evidence that RESV administration commencing after SE onset is highly ben-
eficial for restraining SE-induced oxidative stress, neurodegeneration, neuroinflammation and abnormal 
neurogenesis, all of which have been recognized as epileptogenic changes or precursors of chronic epi-
lepsy development. Considering these, RESV administration seems suitable as an adjunct to AED therapy 
for SE. In such scenario, a suitable combination of AEDs can help in terminating SE emergency whereas 
RESV administration for extended periods after SE would help in modulating the SE-induced oxidative 
stress and neuroinflammation, which may lessen the propensity of SE incidence from progressing into 
a chronic epileptic state. However, follow-up studies will be needed in the future to determine whether 
the extent of neuroprotection provided by RESV administration against SE-induced oxidative stress and 
inflammation is sufficient to prevent or greatly restrain the evolution of SE-induced hippocampal injury 
into chronic epilepsy development typified by SRS and cognitive and mood dysfunction. Furthermore, 
the required dose and duration of RESV treatment after SE to prevent chronic epilepsy development will 
need to be addressed.
Methods
Animals. Young adult (3-4 months old) male F344 rats, obtained from Harlan, were used in this 
study. Animals were housed in an environmentally controlled room with a 12:12-hr light-dark cycle 
and were given food and water ad libitum. All experiments were performed as per the animal protocol, 
approved by the institutional animal care and use committee of the Texas A&M Health Sciences Center 
and Central Texas Veterans Health Care System.
Induction of SE and group assignment. After 7-10 days of acclimatization, SE was induced in 66 
rats through graded intraperitoneal injections of kainic acid (KA, 2.5-5.0 mg/Kg) every hour until they 
displayed either a state of continuous stage IV seizures characterized by bilateral forelimb clonus with 
signs of rearing, or a first stage V seizure typified by bilateral forelimb clonus with rearing and falling 
followed by continuous stages III-V seizures for over 10 minutes12,34–36. Animals were allowed to have 
multiple stages III-V seizures for an hour after the onset of SE and then assigned randomly to RESV or 
VEH groups. The behavioral seizures in both VEH and RESV treated groups were terminated 2 hours 
after the induction of SE through an intraperitoneal injection of diazepam (5 mg/Kg). This SE prototype 
has 20–30% mortality occurring either during SE (due to uncontrolled bouncing and/or tonic-clonic 
seizures) or in the first few days after SE when 3-4 months old rats are employed. Furthermore, 10–20% 
of rats do not meet all SE criteria despite receiving 4-5 injections of KA and such animals were excluded 
from the study. A total of 36 rats met SE criteria and survived the entire duration of the experiment in 
this study.
Treatment regimen and animal numbers utilized for various analyses. Animals received 
intraperitoneal injections of vehicle (VEH, n = 17) or RESV (n = 19, 30 mg/Kg b.w.) after SE, which 
commenced an hour after the onset of SE and continued hourly for three hours on SE day and twice 
daily thereafter for the next 3 days. Subsets of rats were euthanized a day after SE (VEH, n = 4; RESV, 
n = 6) and 4-days after SE (VEH, n = 4; RESV, n = 5) with deep anesthesia followed by decapitation. 
Fresh brain tissues from these animals were harvested for biochemical and molecular biological studies. 
Brain tissues from a group of age-matched naive control rats (n = 6) were also harvested similarly for 
comparison. Additional subsets of rats from both SE groups (VEH, n = 9; RESV, n = 8) were perfused 
4 days after SE for immunohistochemical processing of hippocampal tissue sections and quantification 
of the extent of neurodegeneration, aberrant neurogenesis and neuroinflammation. Hippocampal tissue 
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sections harvested earlier from a group of age-matched naive control rats (n = 6) were also processed for 
immunohistochemistry for comparison.
Tissue processing and immunohistochemistry. Each animal belonging to SE-VEH and SE-RESV 
groups (n = 8-9/group) was deeply anesthetized through isoflurane vapor exposure and then perfused 
through the heart using 4% paraformaldehyde. Animal perfusion and tissue processing protocols are 
detailed in our previous reports12,34. Thirty-micrometer thick cryostat sections were cut coronally 
through the entire septo-temporal axis of the hippocampus and collected serially in 24-well plates 
containing phosphate buffer (PB). Serial sections (every 20th) through the entire hippocampus were 
selected in each of the animals belonging to SE-VEH and SE-RESV groups and processed for immu-
nohistochemical studies, along with tissue sections of similar thickness and comparable levels obtained 
from age-matched naive control animals (n = 6). The studies comprised detection of: (i) neuron-specific 
nuclear antigen (NeuN, a marker of all mature neurons); (ii) markers of subclasses of gamma-amino 
butyric acid (GABA) positive interneurons such as neuropeptide Y (NPY), somatostatin (SST), par-
valbumin (PV) and reelin; (iii) ED-1 (a marker of activated microglia) and (iv) doublecortin (DCX, a 
marker of newly born neurons). The detailed procedures employed for immunohistochemical staining 
for the above markers are described in our previous reports1,12,68–72. In brief, sections were first treated 
with phosphate buffered saline (PBS) solution containing 20% methanol and 3% hydrogen peroxide 
for 20 minutes and then rinsed thrice in PBS. Next, the sections were treated for 30 minutes in PBS 
containing 0.1% Triton-X 100 and an appropriate serum (10%) selected on the basis of the species in 
which the chosen secondary antibody was raised. Sections were then incubated 18-48 hours in primary 
antibody solutions prepared in PBS. The primary antibodies comprised mouse monoclonal anti-NeuN 
(1:1000, Millipore), anti-parvalbumin (1:2000, Sigma), anti Reelin (1:1000, Millipore), and anti ED-1 
(1:1000, Serotech), rabbit monoclonal anti-NPY (1:10,000, Peninsula laboratories) and anti-SST (1:5000, 
Calbiochem), and goat polyclonal anti-DCX (1:200; Santa Cruz Biotechnology). Following primary anti-
body incubation, sections were washed thrice in PBS, incubated in an appropriate biotinylated secondary 
antibody (anti-goat, anti-mouse or anti-rabbit IgG, Vector Laboratories) solution for 60 minutes, washed 
thrice in PBS and treated with avidin-biotin complex reagent (ABC, Vector) for 60 minutes. The perox-
idase reaction was then developed using diaminobenzidine (DAB, Vector). The sections were mounted 
on gelatin coated slides, dehydrated, cleared and cover slipped.
Stereological quantification of neurons, interneurons, activated microglia and newly born 
neurons in the hippocampus. The optical fractionator method in the StereoInvestigator system 
(Microbrightfield Inc., Williston, VT) interfaced with a Nikon E600 microscope through a color digital 
video camera (Optronics Inc., Muskogee, OK) was employed for all cell counts. It comprised counting 
of: (i) NeuN + mature neurons in the dentate hilus (DH), the granule cell layer (GCL), and CA1 and 
CA3 pyramidal cell layers; (ii) NPY-, SST-, PV- and reelin-positive interneurons in the dentate gyrus 
(DG); (iii) ED-1+ activated microglia in the DG, CA1 and CA3 subfields of the hippocampus; and (iv) 
DCX + newly born neurons in the DH. Every 20th section through the entire septo-temporal axis of 
the hippocampus from each animal belonging to RESV, VEH and naive control groups (n = 6/group) 
was employed for this quantification. The methodology utilized for the optical fractionator stereological 
counting is detailed in our earlier reports12,34,68–70. In brief, using a 100X lens, cells were counted in every 
20th section from 50-500 frames (each measuring 40 × 40 μ m) selected through a systematic random 
sampling scheme. The contour of the chosen hippocampal area was first demarcated in every section 
using the tracing function. Next, by entering parameters such as grid size, thickness of the top guard 
zone (4 μ m) and the optical dissector height (i.e. 8 μ m), numbers and locations of counting frames and 
the depth for counting were determined. A computer steered motor-powered stage then permitted the 
section to be evaluated at every counting frame sites. All cells (expressing NeuN, NPY, SST, PV, reelin, 
ED-1 or DCX) that were present within the 8 μ m section depths in each site were counted if they were 
entirely within the counting frame or touching the upper or right side of the counting frame. This 
process was repeated for all sections. A choice in the Stereo Investigator program let the experimenter 
to remain oblivious to the running cell counts until all sections for each animal were completed. The 
StereoInvestigator program later calculated the total number of cells in each chosen region by utilizing 
the optical fractionator formula, as described in our earlier reports12,68.
Tissue processing for biochemical and molecular biology studies. Biochemical and molecular 
biological studies of hippocampal tissues were performed at one-day and 4-days after the induction of 
SE. For these, each animal belonging to SE-VEH and SE-RESV groups (n = 4–6/time-point/group) and 
an age-matched naive control group (n = 6) was euthanized through decapitation following deep anes-
thesia with isoflurane vapor exposure. The brain was rapidly dissected, snap frozen using dry ice and 
stored at minus 80 °C. Once the required numbers of brains from all groups are collected and stored 
for weeks, the entire hippocampus from each side of every brain was micro-dissected following thaw-
ing. Each hippocampus was then cut coronally into six pieces of approximately comparable size along 
its antero-posterior axis. The odd numbered tissue pieces (1, 3 and 5) were processed for biochemical 
assays and the even numbered tissue pieces (2, 4 and 6) were processed for molecular biological stud-
ies. The biochemical studies comprised: (i) quantification of natural byproducts of lipid peroxidation 
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using malondialdehyde (MDA) assay and competitive enzyme-linked immunoassay (ELISA) for 
4-hydroxynonenal (4-HNE); and (ii) ELISAs for pro-inflammatory cytokines such as tumor necrosis 
factor-alpha (TNFα ) and interleukin-6 (IL-6). The molecular biological studies comprised analyses of 
the expression of genes encoding oxidative stress, antioxidant proteins, pro-inflammatory cytokines and 
antiinflammatory cytokines, and genes important for longevity and synaptic plasticity, using quantitative 
real time polymerase chain reaction (qRT-PCR).
Measurement of oxidative stress markers in the hippocampus. The lysate from the hippocam-
pus of each animal was prepared through homogenization in 750 μ l of tissue extraction reagent (Life 
Technologies, Grand Island, NY) with protease inhibitors (Sigma-Aldrich Corp. St. Louis, MO) using 
a sonic dismembrator for 10 seconds. The lysates were centrifuged twice at 12,000 g for 10 minutes at 
4 °C and aliquots of the collected supernatant were stored at -80 °C until used. The extent of oxida-
tive stress in the hippocampus was ascertained through measurement of malondialdehyde (MDA) and 
4-hydroxy-2-nonenal (4-HNE) concentrations, 1-day and/or 4-days after SE. MDA is a byproduct of 
lipid peroxidation and an important biomarker of membrane damage. On the other hand, 4-HNE is 
α , β -unsaturated hydroxyalkenal produced by lipid peroxidation in cells. For MDA analysis, aliquots 
of tissue lysates were processed in duplicates as per the manufacturer’s protocol for “TBARS Assay Kit” 
(Cayman Chemical Company, MI, USA). Briefly, 100 μ l of sample was mixed with an equal amount of 
SDS solution and 4 ml of a color reagent containing thiobarbituric acid in a tube and boiled for 1 hour 
using a water bath. The tubes were then cooled and samples were centrifuged at 1,600 g at 4 °C. The 
supernatant obtained was loaded on colorimetric plate with 150 μ l in each well and absorbance was read 
at 540 nm. The MDA concentration was then determined in brain samples using a calibration curve pre-
pared from standard MDA processed similarly and expressed as nanomoles/mg of brain tissue. The HNE 
protein adducts were measured by following the manufacturer protocol for “OxiselectTM HNE adduct 
competitive ELISA kit” (Cell Biolabs, CA, USA). Briefly, 50 μ l of tissue aliquot and HNE BSA standard 
were added to the wells of HNE conjugate coated plate and incubated at room temperature for 10 minutes 
with shaking. After incubation, 50 μ l of diluted anti-HNE antibody supplied along with kit was added 
to each well of the plate and incubated at room temperature for an hour. Next, wells were washed thrice 
with wash buffer and incubated with 100 μ l of diluted secondary antibody conjugated to HRP for an 
hour. Following this, wells were loaded with 100 μ l of the substrate solution, incubated for 10 minutes 
and the reaction was stopped by the addition of 100 μ l of stop solution to each well. The absorbance was 
read immediately at 450 nm. The assay was performed in duplicates for each sample and concentrations 
thus obtained were expressed as μ g/mg of tissue.
Analyses of the expression of genes related to oxidative stress. Hippocampal samples from 
VEH and RESV treated groups collected 4 days after SE were processed for “The Rat Oxidative Stress 
PCR Array” from Qiagen, along with samples from age-matched naive control animals (n = 4/group). 
The total RNA was first extracted using RNeasy kit (Qiagen, Valencia, CA) by following manufacturer’s 
instructions and methods detailed in our previous report71. The RNA concentration (A260) and quality 
(A260:A280) were determined by Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE). 
Total RNA (1 μ g) was subsequently transcribed to cDNA using the “RT2 First Strand Kit” (Qiagen, 
Valencia, CA) as per manufacturer’s protocol and our previous study73. The Rat Oxidative Stress PCR 
Array from Qiagen profiles the expression of 84 key genes that are relevant for reactive oxygen species 
(ROS) metabolism, oxygen transporters and antioxidants. The reactions were done as per manufacturer’s 
protocol using a CFX96 Real-Time system (Bio-Rad, Hercules, CA). The PCR amplification was fol-
lowed by a melt curve analysis to evaluate the specificity of the reaction. The cycling conditions were as 
described in our previous study73 and the Ct (threshold cycle) values of all wells were exported to Excel 
spreadsheet and analyzed using web based SABiosciences PCR array data analysis software. 2^delta Ct 
values for each gene from different groups were statistically compared.
Measurement of pro-inflammatory cytokines TNF-α and IL-6. Levels of TNFα and IL-6 pro-
teins were quantitated using rat solid phase sandwich ELISA kits (Invitrogen, Carlsburg, CA) using the 
manufacturer’s protocol. Briefly, the diluted samples, known standards and controls were incubated on 
wells of the microtiter strips that were pre-coated with a specific monoclonal antibody. The wells were 
washed and then incubated with a biotinylated secondary antibody. Streptavidin-peroxidase enzyme was 
added to the washed wells to bind to the biotinylated secondary antibody. After removing the unbound 
enzyme through washing, a substrate solution was added. The peroxidase reaction produced a color, 
with an intensity that is directly proportional to the respective concentration of TNFα or IL-6 present 
in the sample.
Analyses of the expression of genes related to inflammation, longevity and cognition. 
Hippocampus samples from VEH and RESV treated groups collected 1 and 4 days after SE were also 
used for measuring the expression of select genes related to inflammation, longevity and cognition, along 
with samples from age-matched naive control animals (n = 4-6/group). The total RNA and cDNA were 
prepared as described above. The template cDNA was next amplified separately using specific primers 
(Qiagen, Valencia, CA) of multiple genes. This comprised genes linked to inflammation (interleukin-1beta 
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[IL-1β ], TNFα , nuclear factor kappa B [NFκ B], interferon-gamma [IFN-γ], IL-4 and IL-10, myeloper-
oxidase [MPO]), and longevity and cognition (NAD-dependent deacetylase sirtuin-1 [SIRT1], Forkhead 
box O3 [FOXO3]). In brief, for each qPCR reaction, 1 μ l template cDNA was mixed with 12.5 μ l of 2X 
SYBR master-mix (SABiosciences, Qiagen, Valencia, CA), 1 μ l of gene specific primer (RT2 qPCR primer 
mix containing 10 μ M each of forward and reverse primers, Qiagen, Valencia, CA) and 10.5 μ l of dH2O 
for a total volume of 25 μ l. Each assay also comprised two housekeeping genes namely GAPDH and Act 
B. After a brief centrifugation, reactions were carried out using a CFX96 Real-Time system (Bio-Rad, 
Hercules, CA). Data collection and analyses were performed as described above.
Statistical Analyses. Statistical analyses were performed using one-way analyses of variance (one-way 
ANOVA) with Newman-Keuls multiple comparison post hoc tests when comparisons involved three or 
more groups. When comparisons involved only two groups, unpaired, two-tailed Student’s-t test was 
employed. Data were expressed as means ± SEM and a p value less than 0.05 was considered as statis-
tically significant.
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